Pendidikan Untuk Kesehatan Perempuan
Comparison of quality of life in patients with cervical cancer given cisplatin-based versus single cisplatin chemoradiation at Sardjito Hospital Yogyakarta
I.M. Mustofa*, H. Pradjatmo*, M. Hakimi*
* Department of Obstetrics & Gynecology, Sardjito Hospital, Yogyakarta*
Objective: Comparing the quality of life in patients with cervical cancer given Cisplatin-based versus single Cisplatin chemoradiation and risk factors that influencing.
Material dan Method: A retrospective cohort study design in 146 patients with cervical cancer. Seventy three patients in each group have completed 1 series of weekly Cisplatin + 5-FU or 3 weekly Cisplatin chemoradiation at Sardjito Hospital Yogyakarta. For assessing the quality of life, the author used EORTC QLQ-C30 and QLQ-CX24. Data distribution was analytically tested by Kolmogorov-Smirnov. Categorical data were tested with Chi-Square, while continous data with Mann-Whitney test. Multivariable analysis used logistic regression.
Result: The results of Mann-Whitney test found significant mean difference almost in all items, except for item of diarrhea in QlQ-C30 and sexual/vaginal function item in QLQ-CX24. The mean value of quality of life in Cisplatin + 5-FU is higher than single Cisplatin (72.60 + 16.98 vs 62.22 + 16.73). We found relationship of high quality of life in Cisplatin + 5-FU chemoradiation 1.73 times than single Cisplatin (RR 1.73; 95% CI 1.14 – 2.61; p = 0,007). The results of multivariable analysis found no significant differences of the types of chemoradiation between Cisplatin + 5-FU versus single Cisplatin (p = 0,239) in quality of life. However, time intervals and stage/surgical treatment variables impact the quality of life with significant differences (p = 0,033 & p = 0,000).
Conclusion: No significant differences in quality of life of patients with cervical cancer on the type of chemoradiation between combination of Cisplatin + 5-FU or single Cisplatin at Sardjito Hospital Yogyakarta.
Keywords: Quality of life, cervical cancer, Cisplatin, 5-Fluorouracil